{"status": "OK", "response": {"docs": [{"type_of_material": "Letter", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "To the Editor: ''Two Nations Fight AIDS'' (editorial, Nov. 23) offers an unduly bleak assessment of China's chances for success in the campaign to provide H.I.V./AIDS treatment to all who need it. Although the challenges you describe are real, the recent AIDS conference in Beijing, which was attended by former President Bill Clinton and numerous Chinese government officials, sent a signal that China does take AIDS seriously.", "headline": {"main": "China's Hazy Battle With a Scourge"}, "abstract": "Yale School of Nursing Prof Ann B Williams letter contends Nov 23 editorial offers unduly bleak assessment of China's chances in campaign to provide HIV/AIDS treatment to all who need it; cites evidence that Chinese officials take AIDS seriously", "print_page": "42", "word_count": 174, "_id": "4fd2776c8eb7c8105d838e5f", "snippet": "To the Editor:    ''Two Nations Fight AIDS'' (editorial, Nov. 23) offers an unduly bleak assessment of China's chances for success in the campaign to provide H.I.V./AIDS treatment to all who need it. Although the challenges you describe are real, the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/28/opinion/l-china-s-hazy-battle-with-a-scourge-333220.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "WILLIAMS, ANN"}, {"name": "glocations", "value": "CHINA"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}], "byline": null, "document_type": "article", "pub_date": "2003-11-28T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Several clinical trials of a widely used anemia drug have been halted in the last few weeks after patients developed a higher-than-expected number of blood clots, according to doctors and Johnson & Johnson, the seller of the drug. The development has added more evidence that the drug, Procrit, and perhaps similar drugs sold by Amgen, could pose risks if used more than is necessary to reverse anemia, doctors said. But several doctors said the drugs would not pose a danger if used in appropriate amounts.", "headline": {"main": "Drug Company Halts Trials Of Procrit"}, "abstract": "Johnson & Johnson and doctors halt several clinical trials in which drug Procrit was used to raise hemoglobin levels in blood beyond levels needed to treat anemia in order to make cancer therapy more effective, after patients developed higher-than-expected number of blood clots; doctors see mounting evidence that drug, and perhaps similar drugs sold by Amgen, Epogen and Aranesp, could pose risks if used more than is necessary to halt anemia; drugs are versions of natural hormone erythropoietin, or EPO (M)", "print_page": "1", "word_count": 1083, "_id": "4fd248d38eb7c8105d7e579e", "snippet": "Several clinical trials of a widely used anemia drug have been halted in the last few weeks after patients developed a higher-than-expected number of blood clots, according to doctors and Johnson & Johnson, the seller of the drug.     The development...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/27/business/drug-company-halts-trials-of-procrit.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "JOHNSON & JOHNSON INC"}, {"name": "organizations", "value": "AMGEN INC"}, {"name": "subject", "value": "PROCRIT (DRUG)"}, {"name": "subject", "value": "EPOGEN (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARANESP (DRUG)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "CHEMOTHERAPY"}, {"name": "subject", "value": "ERYTHROPOIETIN (DRUG)"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "HEMOGLOBIN"}, {"name": "subject", "value": "ANEMIA"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2003-11-27T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "GIVEN the passage this week of Medicare legislation, which would privatize much more of this vast program than anyone expected, you might think there would be plenty of evidence that such a shift would reduce the growth of health care costs over time. After all, that is the main reason the bitterly fought bill passed. Many in Congress believe that Medicare, the nation's 38-year-old health program for the elderly, will simply not be affordable once baby boomers reach retirement age.", "headline": {"main": "Economic Scene; Does Medicare or private insurance do a better job of controlling health care costs?"}, "abstract": "Jeff Madrick Economic Scene column cites research indicating Medicare may well hold down health care costs better than private industry does; notes that even many advocates of privatization concede private health insurers have shown no significant ability to control costs better than Medicare; notes advocates see privatization offering more choice; graph comparing rise in medical care payments (M)", "print_page": "2", "word_count": 1032, "_id": "4fd29cc88eb7c8105d87e3d4", "snippet": "GIVEN the passage this week of Medicare legislation, which would privatize much more of this vast program than anyone expected, you might think there would be plenty of evidence that such a shift would reduce the growth of health care costs over...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/27/business/economic-scene-does-medicare-private-insurance-better-job-controlling-health.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "PRIVATIZATION"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Jeff", "lastname": "Madrick"}], "original": "By Jeff Madrick"}, "document_type": "article", "pub_date": "2003-11-27T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "As Congress edged closer to passing a Medicare drug benefit that prohibits the government from using its buying clout to win discounts, one thing was clear: the drug industry appeared on the cusp of an enormous victory, gained in part by millions in political donations and an expensive lobbying campaign. But like everyone else, drug executives flipped on their computers this morning and found a raft of unsolicited e-mail messages for discounted drugs from Canada -- a sign that the industry's political and business troubles are far from solved.", "headline": {"main": "Drug Makers Move Closer To Big Victory"}, "abstract": "Passage of Medicare drug benefit will hand drug industry enormous victory that was gained in part by millions of dollars in political donations and expensive lobbying campaign; effort helps industry avoid legalization of widescale imports from Canada, as well as price controls (M)", "print_page": "20", "word_count": 728, "_id": "4fd2346b8eb7c8105d7c56ad", "snippet": "As Congress edged closer to passing a Medicare drug benefit that prohibits the government from using its buying clout to win discounts, one thing was clear: the drug industry appeared on the cusp of an enormous victory, gained in part by millions in...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/25/us/drug-makers-move-closer-to-big-victory.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "CANADA"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "LOBBYING AND LOBBYISTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2003-11-25T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "Over the past two decades, conflicting medical ideas have surfaced about narcotic painkillers, the drugs that Rush Limbaugh blames for his addiction while being treated for chronic back pain. And both of them, not surprisingly, have centered on the bottom-line question: just how great a risk of abuse and addiction do narcotics pose to pain patients? Throughout much of the last century, doctors believed that large numbers of patients who used these drugs would become addicted to them. That incorrect view meant that cancer sufferers and other patients with serious pain were denied drugs that could have brought them relief.", "headline": {"main": "The Delicate Balance Of Pain and Addiction"}, "abstract": "Researchers questioning risks of abuse and addiction from prescribing narcotics to patients in pain find conflicting answers from recent studies; Dr Russell Portenoy, Beth Israel Medical Center pain medicine and palliative care department chairman, holds addiction is highly limited problem and sees pain management as important aspect of good patient care; many researchers agree biggest risk of addiction seems to be for those individuals already pre-disposed to abusing drugs; photos (M)", "print_page": "1", "word_count": 1419, "_id": "4fd2776a8eb7c8105d838d1b", "snippet": "Over the past two decades, conflicting medical ideas have surfaced about narcotic painkillers, the drugs that Rush Limbaugh blames for his addiction while being treated for chronic back pain. And both of them, not surprisingly, have centered on the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/25/science/the-delicate-balance-of-pain-and-addiction.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "PORTENOY, RUSSELL K"}, {"name": "organizations", "value": "BETH ISRAEL MEDICAL CENTER"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PAIN"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "DRUG ABUSE AND TRAFFIC"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Barry", "lastname": "MEIER"}], "original": "By BARRY MEIER"}, "document_type": "article", "pub_date": "2003-11-25T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The Medicare bill about to clear Congress is the latest example of how budget discipline is being given short shrift at both ends of Pennsylvania Avenue, critics here and on Wall Street say. By official calculations, the tax cuts and increases in benefits enacted this year alone will increase the national debt by more than $750 billion over the next decade, and the actual amount could be much larger.", "headline": {"main": "Congressional Memo; Spending Discipline Proves Unfashionable This Year"}, "abstract": "Medicare bill about to clear Congress is latest example of how budget discipline is getting short shrift at both ends of Pennsylvania Avenue this year; tax cuts and benefits increases enacted this year alone will increase national debt by at least $772 billion over next decade; photo; Pres Bush, on campaign trail, emphasizes 'spending discipline' but has supported expensive legislation (Congressional Memo) (M)", "print_page": "20", "word_count": 967, "_id": "4fd231bd8eb7c8105d7c10fa", "snippet": "The Medicare bill about to clear Congress is the latest example of how budget discipline is being given short shrift at both ends of Pennsylvania Avenue, critics here and on Wall Street say.    By official calculations, the tax cuts and increases in...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/25/us/congressional-memo-spending-discipline-proves-unfashionable-this-year.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "TAXATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "ELECTION ISSUES"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "NATIONAL DEBT (US)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "BUDGETS AND BUDGETING"}], "byline": {"person": [{"firstname": "David", "middlename": "E.", "lastname": "ROSENBAUM", "rank": 1, "role": "reported", "organization": ""}], "original": "By DAVID E. ROSENBAUM"}, "document_type": "article", "pub_date": "2003-11-25T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Style Desk", "lead_paragraph": "IN his quest to reach the age of 143, Michael A. Sherman is making his peace with doughnuts. Renouncing potato skins and chocolate-chip pancakes was no problem, but he just hasn't found a substitute for a glazed, oven-warm bear claw oozing with apple filling. ''I love them, but the larger specimens of that species can approach 1,000 calories,'' he said a few weeks before Thanksgiving, a holiday he can't get overly excited about. ''That's almost as much as I allow myself in a whole day.'' To say Mr. Sherman is on a diet is to say NASA's Voyager spacecraft, still twinkling at the far edge of our solar system, is on a Sunday drive. Six years ago, Mr. Sherman put himself on the most brutal calorie-reduction plan imaginable. Not that he was especially overweight at 5-foot-5 and 145 pounds. But by switching from pizza and chips to flaxseed, brewer's yeast and sprouts, he whittled his daily caloric intake to less than 1,600, and dropped his weight precipitously, dumbfounding his friends and family.", "headline": {"main": "Food for Holiday Thought: Eat Less, Live to 140?"}, "abstract": "Article on subculture of scientists, philosophers, futurists and other high-minded anorectics who have taken up and advocate calorie restriction, or CR, diet, in effort to substantially extend life span; Calorie Restriction Society has about 900 ultralean members worldwide; photos (L)", "print_page": "1", "word_count": 2267, "_id": "4fd231c28eb7c8105d7c1415", "snippet": "IN his quest to reach the age of 143, Michael A. Sherman is making his peace with doughnuts. Renouncing potato skins and chocolate-chip pancakes was no problem, but he just hasn't found a substitute for a glazed, oven-warm bear claw oozing with apple...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/11/23/style/food-for-holiday-thought-eat-less-live-to-140.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "CALORIE RESTRICTION SOCIETY"}, {"name": "subject", "value": "DIET AND NUTRITION"}, {"name": "subject", "value": "WEIGHT"}, {"name": "subject", "value": "LONGEVITY"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "David", "lastname": "HOCHMAN"}], "original": "By DAVID HOCHMAN"}, "document_type": "article", "pub_date": "2003-11-23T00:00:00Z", "section_name": "Health; Style"}], "meta": {"hits": 7, "offset": 0, "time": 77}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}